Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2015-01, Vol.41 (1), p.149-149
Main Authors: Hendy, P., Hart, A.
Format: Article
Language:English
Subjects:
Adalimumab
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - blood
Antibodies, Monoclonal, Humanized - therapeutic use
Colitis, Ulcerative - drug therapy
Gastrointestinal Agents - administration & dosage
Gastrointestinal Agents - blood
Gastrointestinal Agents - therapeutic use
Humans
Infliximab
Tumor Necrosis Factors - antagonists & inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.13011